Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $8.3 billion.

  • Gsk's Long-Term Deferred Tax rose 184.73% to $8.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 billion, marking a year-over-year increase of 184.73%. This contributed to the annual value of $8.6 billion for FY2024, which is 1479.85% up from last year.
  • Per Gsk's latest filing, its Long-Term Deferred Tax stood at $8.3 billion for Q3 2025, which was up 184.73% from $8.8 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Long-Term Deferred Tax peaked at $8.8 billion during Q2 2025, and registered a low of $421.3 million during Q1 2022.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $7.1 billion (2023), whereas its average is $6.9 billion.
  • As far as peak fluctuations go, Gsk's Long-Term Deferred Tax tumbled by 9291.38% in 2022, and later skyrocketed by 151842.39% in 2023.
  • Over the past 5 years, Gsk's Long-Term Deferred Tax (Quarter) stood at $7.0 billion in 2021, then decreased by 5.65% to $6.6 billion in 2022, then increased by 13.13% to $7.5 billion in 2023, then increased by 15.52% to $8.7 billion in 2024, then fell by 4.06% to $8.3 billion in 2025.
  • Its last three reported values are $8.3 billion in Q3 2025, $8.8 billion for Q2 2025, and $8.1 billion during Q1 2025.